Vident Investment Advisory’s Idexx Laboratories IDXX Stock Holding History

Vident Investment Advisory’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,087	Closed	-$546K	–	487
2023 Q2	$546K	Buy	1,087 +37	+4%	+$17.7K	0.02%	666
2023 Q1	$525K	Buy	1,050 +249	+31%	+$119K	0.02%	762
2022 Q4	$327K	Buy	+801	New	+$311K	0.01%	856
2022 Q1	–	Sell	-813	Closed	-$536K	–	1302
2021 Q4	$536K	Sell	813 -175	-18%	-$110K	0.01%	901
2021 Q3	$615K	Buy	988 +76	+8%	+$51.1K	0.02%	826
2021 Q2	$576K	Sell	912 -167	-15%	-$92.2K	0.02%	800
2021 Q1	$528K	Sell	1,079 -198	-16%	-$99.2K	0.02%	771
2020 Q4	$638K	Sell	1,277 -120	-9%	-$53.7K	0.03%	652
2020 Q3	$549K	Sell	1,397 -345	-20%	-$128K	0.03%	640
2020 Q2	$576K	Buy	+1,742	New	+$504K	0.03%	610

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Vident Investment Advisory's IDXX Position: Q3 2023 in Review

Vident Investment Advisory sold out of Idexx Laboratories (IDXX) in Q3 2023, closing a stake of 1,087 shares — an estimated $546K sold.

Vident Investment Advisory first reported a position in IDXX in Q2 2020 and held it in 10 quarters. The position peaked at $638K in Q4 2020. 1,059 funds tracked by Wall St. Rank hold IDXX as of Q3 2023.

Vident Investment Advisory reported no remaining Idexx Laboratories position as of Q3 2023 after selling out during the quarter.
Vident Investment Advisory sold 1,087 Idexx Laboratories shares in Q3 2023, an estimated $546K.
Vident Investment Advisory first reported a position in Idexx Laboratories in Q2 2020 and held it in 10 quarters.
Vident Investment Advisory's Idexx Laboratories position peaked at $638K in Q4 2020.
1,059 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.